M‑89

• Description:

  M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia. M-89 inhibits the cell growth in leukemia cell lines carrying MLL fusion[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/m-89.html

• Purity:

  99.14

• Solubility:

  DMSO : 7.35 mg/mL (ultrasonic)

• Smiles:

  O=C (NC) O[C@@H]1[C@@H] ([C@]2 (C3CCN (CC4CN (C5=CC=C (S (=O) (C6=CC=NC=C6) =O) C=C5) C4) CC3) CN (C) CC7=C2C=CC=C7) CCC1

• Molecular Formula:

  C37H47N5O4S

• Molecular Weight:

  657.87

• References & Citations:

  [1]Aguilar A, et al. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. J Med Chem. 2019 Jul 11;62 (13) :6015-6034.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2363165-42-6